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1. Introduction 
Sarcoidosis, a multisystem disorder, results in the production of multiple non-caseating 
granulomas capable of affecting all organs of the body. It usually occurs in patients between 
the ages of 10 and 40 years of age in 90% of cases. The prevalence has been reported to be 
10-20 per 100,000 in the general population however the annual incidence is 107 per 100,000  
(Rybicki, Major et al. 1997). There also appears to be a variation in the racial prevalence of 
the disease with Caucasians having a 0.85% lifetime risk for the disease while the lifetime 
risk for Black Americans is 2.5% (Rybicki, Major et al. 1997). The racial implications of the 
disease are not just confined to prevalence, evidence suggests that along with the increased 
prevalence of Sarcoidosis Black American patients also have a more acute and severe 
process in contrast to the usually slow insidious symptoms commonly seen in Caucasian 
patients (Newman, Rose et al. 1997). Familial clustering has also been identified in linkage 
studies and this has identified the short arm of chromosome 6 as the area of most interest 
(Baughman, Lower et al. 2003). 
Despite intense study an exact etiology for Sarcoidosis has remained elusive for 
investigators, leaving many to speculate as to the pathogenesis of the disease. Most 
commonly the respiratory system is the primary target of the disease, in addition to this the 
skin and eyes are regularly affected leading researchers to believe that an environmental 
cause was the most likely cause. Many associations have been suggested ranging from wood 
burning stoves to inorganic particles, insecticides and moulds (Bresnitz and Strom 1983; 
Newman, Rose et al. 2004; Rybicki, Amend et al. 2004). The recent advancement in 
technology and the use of polymerase chain reaction to amplify the genetic products of 
sampled tissue resulted in the discovery of mycobacterial antigens in serum samples taken 
from patients with Sarcoidosis (Song, Marzilli et al. 2005). Most investigators however 
favour an immune response abnormality and that the antigen in question is of lesser 
significance. Evidence for this was seen with the association between human leukocyte 
antigen variants and Sarcoidosis, especially the good correlation between HLA-DQB1*0201 
and acute disease with a good prognosis (Sato, Grutters et al. 2002). 
The majority of Sarcoidosis affected individuals do not develop progressive fibrotic disease; 
indeed, two thirds of patients will have a remission with half achieving this within three 
years. The response once achieved is also favourable with less than 5% of patients achieving 
remission in one year subsequently having a relapse. In essence this results in one third of 
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patients developing progressive disease in addition to the 5% of patients who have a 
relapse. While the numbers with significant disease are less than the potential that might be 
affected, with 90% of patients presenting with respiratory impairment, the implications for 
surgery could be significant.  
In Mississippi, over 47years ago, the first human lung transplant was performed on a patient 
with emphysema and lung carcinoma of the left main bronchus (Hardy, Webb et al. 1963). 
The patient survived for 18 days; 20 years later surgeons in Toronto performed another 
procedure with the use of coronary bypass technology and since then it has developed into a 
significant part of the clinical armamentarium used to treat a number of end stage lung 
diseases including Sarcoidosis. Improved outcome from lung transplantation has been 
attributed to better use of immunosuppression, surgical techniques and better donor 
selection. Recipients have also been scrutinised for acceptability with some believing that a 
multisystem disease such as Sarcoidosis might result in increased deaths postoperatively. 
This turned out to be unfounded as long as the individual patients fulfilled the routine 
testing requirements outlined below.  
In order to assist in making the process of transplantation more transparent and equitable 
the method by which lungs are distributed in the United States has recently been updated. 
Diseases are given a number calculated from clinical parameters which is weighted based on 
the likelihood of surviving one year before transplantation and one year after 
transplantation. The calculated number, referred to as the LAS (lung allocation score), is 
based on historical data and is to be reviewed on a regular basis to maintain its 
accuracy(Egan, Murray et al. 2006). Sarcoidosis figures are therefore based on previous 
outcomes and survival data, and due to the low numbers of transplants performed 
historically for Sarcoidosis, patients may benefit when the reviews are performed. Outside 
the United States many units rely on clinical parameters and regular outpatient reviews to 
decide on urgency both for listing and organ allocation. This review will detail when 
patients should be referred and listed for lung transplantation and the complications that 
can be encountered during the process. 
2. Diagnosis 
To accurately diagnose Sarcoidosis three criteria are required. These include consistent 
clinical and radiographical features, supporting histology classically described as non-
caseating epithelioid cell granulomas, and the exclusion of other causes of granulomatous 
disorders. Unless patients present with a characteristic Lofgren’s syndrome a biopsy of the 
affected organ is usually necessary, however, considering the multisystem nature of the 
disease the area easiest to access can be used, for example a cervical or axillary lymph node.  
2.1 Clinical presentation 
Up to 50% of patients with Sarcoidosis may be asymptomatic at the time of diagnosis. Many 
patients will in fact be suspected of having the disease based on findings during incidental 
radiological testing. If present the respiratory system is most commonly involved with 
symptoms reported in 40% of patients. These symptoms usually manifest as dyspnoea, 
cough which can be productive or non-productive of sputum, chest pain, or haemoptysis in 
decreasing order of frequency. Constitutional symptoms are also reported in up to 40%with 
patients reporting fatigue, malaise, weight loss, night sweats, chills and fever. These features 
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are also more frequently reported in Black patients and patients from the Indian 
subcontinent. 
Acute presentation with Lofgren’s syndrome has been reported in 9-34% of cases 
comprising arthritis, erythema nodosum and bilateral hilar adenopathy (Siltzbach, James et 
al. 1974). Women may present differently with this syndrome affected predominantly with 
erythema nodosum, while men usually develop ankle periarticular inflammation and no 
erythema nodosum. The frequency of other organ involvement including liver, spleen, 
cardiac, ocular, central and peripheral nerve involvement is listed in Table 1.  
 
 
 
Table 1. Frequency of Clinical symptoms 
2.2 Radiological features 
As only 50% of patients have symptoms at diagnosis radiological features have become 
central to diagnosing and staging Sarcoidosis. Although there is a pantheon of modalities 
now available for radiological investigation not all have been assessed in Sarcoidosis. Chest 
X-Ray (CXR) remains the commonest first investigation to raise the suspicion of Sarcoidosis. 
As CXR has long been available the common abnormalities associated with Sarcoidosis are 
well described. These include bilateral hilar lymphadenopathy, with or without interstitial 
infiltration, nodular changes or fibrosis. This has resulted in the classification of Sarcoidosis 
into four stages based on the array of findings that might be present. Stage 1 is bilateral hilar 
lymphadenopathy without parenchymal infiltration, stage 2 is bilateral hilar 
lymphadenopathy with parenchymal infiltration, stage 3 is parenchymal infiltration without 
hilar enlargement, and stage 4 has hilar retraction, bullae, fibrotic banding, traction 
bronchiectasis and diaphragmatic tenting (Scadding 1961).  
Computed tomography (CT) develops superior views of the thoracic cage and so has 
superseded the CXR for usefulness in the diagnostic algorithm. CT scanning can identify 
subtle changes in the parenchyma allowing staging to be more accurately applied to the 
patient. Identification of ground glass opacification in this way may also identify steroid 
responsive disease (Murdoch and Muller 1992). In addition parenchymal markings 
identified before bronchoscopy allows a targeted approach to transbronchial biopsies. 
Clinical Symptoms   Rate (%) 
 
Asymptomatic   12-50% 
Constitutional Symptoms   15-40% 
Respiratory Symptoms  15-40% 
Skin     10-35% 
Eyes     10-25% 
Joints     5-17% 
Neurological    5% 
Cardiac    5% 
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Although no longer part of routine assessment due to poor sensitivity Gadolinium 67 
scanning has previously been used. If present a classical distribution of uptake involving the 
lung parenchyma, hilar nodes, parotid and lacrimal gland (the ’panda’ sign) favours a 
diagnosis of Sarcoidosis (Sulavik, Spencer et al. 1990). It has been suggested however that 
Gadolinium may be useful in the diagnosis of cardiac Sarcoidosis in combination with other 
modalities (Niida, Isoda et al. 2009). 
A recent report on positron emission tomography (PET) scanning suggests that using 
fluoro-alpha-methyltyrosine in combination with 18-F-fluorodeoxyglucose-PET may be 
beneficial in allowing a better distinction between malignancy and Sarcoidosis (Shulman, 
Latkany et al. 2009).  Magnetic resonance imaging on the other hand has been extensively 
used in the diagnosis of systemic and especially cardiac Sarcoidosis (Mehta, Lubitz et al. 
2008). Its use in parenchymal lung Sarcoidosis is limited; however, there is a role for its use 
to rule out the presence of mediastinal fibrosis as a cause of pulmonary artery impingement 
syndrome (Dhote, Vignaux et al. 2003).  
2.3 Investigations and diagnostics 
Historically the Kveim-Siltzbach test has been utilized for diagnosis and involves the 
intradermal injection of a homogenate of human Sarcoid tissue, this is followed up four 
weeks after the injection when a papule has formed at the site. The papule is then biopsied 
and assessed histologically for classical histological features of Sarcoidosis. Currently its use 
is limited by the lack of commercial antigen availability, current controls with regards the 
use of human tissue and new preparations requiring validation in vivo therefore it is 
reserved for use when lesions are not easily accessible, which in reality is uncommon 
(Iannuzzi, Rybicki et al. 2007).  
Histological findings in Sarcoidosis are characteristic but by no means are they 
pathognomic. The classically described epithelioid granuloma may be found in any organ of 
the body and usually consists of distinct lesions with epithelioid cells and multinucleated 
giant cells at the centre. In the lung it usually involves the peri bronchial, interstitial and 
subpleural compartments. Associated vasculitis is not a common feature and when present 
other diagnoses should be considered in the differential. Indeed the granulomas themselves 
may be preceded by an interstitial pneumonitis with macrophage and lymphocyte 
infiltrates, although the exact relationship between the extent and severity of these activated 
macrophages and lymphocytes and the extent of granuloma formation subsequently is not 
well understood. The finding of non–caseating granulomas requires further evaluation in 
order to exclude other causes some of which are listed in Table 2. 
Laboratory investigations have been poor in confirming the diagnosis of Sarcoidosis but 
helpful in ruling out other possible causes. Non-caseating granulomas associated with 
Sarcoidosis are known to produce angiotensin converting enzyme and research has shown it 
to be elevated in 75% of patients with Sarcoidosis (Studdy and Bird 1989).  Its use as a 
diagnostic test, however, has been hindered because the level can be raised in many other 
diseases some of which are listed in Table 2. Bronchoalveolar lavage samples taken at 
bronchoscopy have found an associated imbalance in the CD4/CD8 ratio in Sarcoidosis. 
When this ratio is elevated to greater than 3.5 it has a specificity of 95%, unfortunately the 
specificity is low at 59% (Costabel, Bonella et al. 2010). Lavage samples also assist in ruling 
out many of the infective causes of granulomatous disease.  
www.intechopen.com
 
Lung Transplantation for Pulmonary Sarcoidosis  
 
167 
 
Table 2. Differential Diagnosis for Non Caseating Granulomas 
Use of lung function testing may contribute to diagnosis if the pattern of spirometry is 
consistent. Usually however its use is reserved for follow up and assessment of treatment. 
Most patients have a restrictive deficit on spirometry but in 50% there is a coexisting 
obstruction as evidenced by a reduced ratio of forced expiration in one second to forced 
vital capacity. Interestingly, this obstruction has been shown in some patients to be 
reversible (Baughman, Teirstein et al. 2001; Shorr, Torrington et al. 2001). The advantage of 
lung function testing in Sarcoidosis is that it may highlight other disease for example in 
patients with a conspicuously low diffusion capacity for carbon monoxide out of proportion 
for the spirometric values might suggest a pulmonary vascular component is present. As a 
means of follow up in patients commenced on treatment lung function is useful with studies 
suggesting that abnormalities returns to normal in 80% of patients after two years (Judson, 
Baughman et al. 2003). 
Acquiring tissue for histological assessment has also changed over the recent decades. While 
tests like the Kveim test had their place, the most commonly affected organ is the lung and 
as a result this has become the most commonly accessed site for most patients. Open or 
video-assisted thoracoscopic biopsy remains the gold standard as direct visualisation allows 
identification of granulomas in 90% of cases. Mediastinoscopy has also been performed and 
while it possesses a high sensitivity rate it is an invasive procedure with a morbidity rate 
that may render it unjustifiable in many cases. 
Development of the fibreoptic bronchoscope has allowed targeted transbronchial biopsies to 
be performed whish has resulted in a high yield for lesions in a peribronchial distribution. A 
minimum of four transbronchial biopsies are needed to guarantee sufficient tissue for 
diagnosis, while reports using this method demonstrated a sensitivity of 90%(Gilman and 
Wang 1980). The development of endobronchial ultrasound has also advanced the 
diagnostic capabilities of bronchoscopy. The advantage of this approach is that not only can 
transbronchial lung biopsies be performed but enlarged mediastinal lymph nodes can also 
be targeted for tissue sampling. The use of endobronchial ultrasound in many centres have 
negated the need to perform mediastinoscopy, and in expert hands the sensitivities can 
Inflammatory Sarcoidosis 
  Berylliosis 
  Granulomatous Vasculitis 
  Eosinophilic Granuloma 
  Hypersensitivity Pneumonitis 
  Crohn’s Disease 
 
Infection  Mycobacterial Infections  
  Fugal infections   
  Syphillis   
  Leprosy    
  Catscratch Disease   
  Parasitic Infection 
 
Neoplasia Carcinoma 
  Lymphoma 
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approach 96% with specificities of 100% (Costabel, Bonella et al. 2010). The safety profile of 
linear endobronchial ultrasound is also superior to that of mediastinoscopy and in many 
centres where it is available it has become the investigation of choice.  
It remains difficult to devise a severity index for Sarcoidosis although there have been some 
attempts. The six minute walk test has significant age and racial variability however lung 
function and diffusion capacity race, immunosuppression use and organ involvement have 
all been incorporated into an algorithm of severity however it remains to be validated 
(Wasfi, Rose et al. 2006; Alhamad 2009). 
3. Treatment 
Most patients with Sarcoidosis will recover spontaneously and don’t require any 
pharmacological treatment, in those that do the most commonly used agents are 
corticosteroids. These are usually indicated when patients are significantly symptomatic, 
have decreasing lung function or diffusion capacity over a 3-6 month period, or have 
advancing radiological disease. Treatment is also indicated for extrapulmonary disease 
including neurological, ocular, renal calcification or hypercalcaemia (Baughman, Costabel et 
al. 2008).  Other agents have also been assessed for use but these are usually reserved for 
those who have had a poor response to corticosteroids, have side effects or in patients who 
have coexistent adverse events and are intolerant of lower doses of corticosteroids (1999). 
Alternative therapies have included methotrexate, most commonly, but also azathioprine 
and leflunamide (Baughman, Costabel et al. 2008). These agents can be used either alone or 
in combination, however, if the response is still unsatisfactory Infliximab (tumour necrosis 
factor-alpha antagonist) can be considered as an alternative. While a number of other agents 
have been considered useful their use has delivered unsatisfactory results. Some of the 
agents trialled include colchicine, cyclophosphamide, mycophenylate mofetil, 
pentoxyphylline and non-steroidal anti-inflammatory agents (Fazzi 2003).  
3.1 Timing of transplantation 
Referral for transplantation has always been the Achilles heal of Sarcoidosis treatment. Of 
particular concern in Sarcoidosis is the difficulty gauging the extent of organ involvement, 
identifying which patients will respond to treatment, and which test is the best prognostic 
indicator. Factors that need to be considered when deciding about the timing of lung 
transplant referral include making sure all avenues of treatment have been exhausted leaving 
lung transplantation as the ’last option’, prognosis needs to be within the transplantation 
window where the patient has a survival advantage from surgery, while the patient also needs 
to be in sufficient health to survive the procedure. Most transplantation centres accept a 
combination of factors to decide when patients should be accepted for transplant workup.  
Extensive fibrocystic disease in stage 4 disease is more likely to derive benefit from lung 
transplantation. Other stages of disease also need to be observed closely in the outpatient 
setting to watch for worsening radiological changes and clinical status as this may be the 
onset of treatment failure. Arterial blood gases revealing a PaCO2 > 6.7 kPa (50 mm Hg) or a 
PaO2 < 7.3 kPa (55 mm Hg) are suggestive of more advanced disease, although, while they 
are evidence of more extensive disease they have not been found to be useful in terms of 
prognosis or identification of progressive disease. Lung function is also a useful indicator 
when following patients and a forced vital capacity between 40-50% with or without a 
declining diffusing capacity below 40% are likely to be symptomatic on exertion if not at rest 
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and should be referred for consideration (Judson 1998). Another factor to take into 
consideration is the impact of disease on quality of life and the patient’s ability to cope with 
the disease. If the patient satisfies some or all of these parameters then referral for transplant 
assessment is prudent. 
Recently the development of pulmonary hypertension has been shown to be a good 
discriminator for future survival (Corte, Wells et al. 2010). Research has revealed that the 
likelihood of mortality on a lung transplant waiting list with a diagnosis of Sarcoidosis was 
equivalent to that for patients with idiopathic pulmonary fibrosis although Sarcoidosis 
patients were less likely to receive a transplant. For Sarcoidosis patients pulmonary 
hypertension had more impact on the disease than for those with idiopathic pulmonary 
fibrosis and may have contributed to the Sarcoidosis deaths (Shorr, Davies et al. 2002). 
Evidence of clinical decline with or without a decline in lung function or diffusion capacity 
should prompt investigation with an echocardiogram, if there is evidence of onset of 
pulmonary hypertension referral for consideration of lung transplantation should be 
considered. 
3.2 Lung transplantation workup 
Screening is used in order select the most appropriate patients for the process of lung 
transplantation. The process ensures not only the appropriate choice of recipient but also 
ensures that the donor families can see that due diligence is performed with respect to the 
ultimate allocation the donor organs. Recent data shows that for all deceased donor lung 
transplants the 1, 5, and 10 year survival is 83, 54 and 29 percent respectively (OPTN/SRTR 
2009 ). Patients with a 20-30% one year survival should be considered appropriate for lung 
transplant work up (Christie, Edwards et al. 2008).  
There are a number of tests that are performed as part of transplant workup that are in no way 
particular to one or other of the many diseases that are considered suitable for lung transplant. 
These are investigations required to assist in guiding the patient successfully through the 
process and are listed in table 3. Sarcoidosis is a multisystem disorder and therefore potentially 
represents a higher risk to transplant recipients in terms of post-operative complications. A 
number of other organs may be involved and so diligent pretransplant screening needs to be 
undertaken to optimize decision making prior to surgery.  
Additional factors that are of particular concern when assessing patients with Sarcoidosis 
include the involvement of the thoracic cage. Patients with advanced disease, especially 
stage 4 disease associated with fibrocystic changes may present with mycetomas or 
pneumothoraces. Mycetomas causing haemoptysis may cause significant difficulty prior to 
surgery however most difficulty arises after transplantation with immunosuppression 
treatment (Rafferty, Biggs et al. 1983). If any fungal infection is brought through the 
operation there is a significant risk of anastomotic breakdown. Therefore patients with any 
evidence of cystic lesions on radiology investigations receive bilateral lung transplants 
decreasing this risk. Multiple pneumothoraces or prolonged thoracotomy tube placed as 
therapy may also result in pleural reaction and fibrosis that can hinder dissection at the time 
of transplantation. If this is extensive or if pleurodesis has been carried out the case may be 
too difficult with a high risk of bleeding, more often than not however, patients can be wait-
listed with extra dissection time added into the protocol on the night.  
In addition to pleural disease patients who have extensive mediastinal involvement need 
careful assessment as mediastinitis also can result in difficult dissection during surgery, in 
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addition, if there is any evidence of impingement of the pulmonary artery with right heart 
failure then stenting of the pulmonary arteries may improve symptoms significantly 
delaying or negating the need for listing (Figure 1C). Ventilation/perfusion scans are 
unreliable in this instance as the significance of the obstruction may be difficult to assess and 
a Magnetic Resonance Angiogram gives a detailed outline of the mediastinal structures 
completing the workup. 
 
 
Fig. 1. Sarcoidosis Complications impacting on surgery: A) Tracheal deviation, B) pleural 
reaction, C) mediastinitis causing pulmonary artery outlet obstruction. 
The skin, the second most common organ to be involved with up to 25% of patients affected 
to some degree, usually manifests itself in the form of macules, papules, plaques or indeed 
the classical lupus pernio involvement of the lips, cheeks and nose (Yanardag, Pamuk et al. 
2003). While this type of disease is not a contraindication to lung transplantation one needs 
to be mindful of the potential for impaired site healing or indeed wound infection if the 
cutaneous region around the potential incision site is involved.  
The liver and spleen may also be involved with 10 percent of patients having an elevation 
in their alkaline phosphatase and aminotransferases (Baughman, Teirstein et al. 2001). CT 
analysis of the hepatosplenic system in Sarcoidosis patients found that the liver 
developed granulomatous lesions in 5 percent of patients with the spleen having 
granulomatous involvement in 15 percent. While these figures might be higher than 
 
A B 
C 
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previously thought the nature of liver disease in Sarcoidosis is mainly of insidious onset 
and clinically quiescent (Scott, Berman et al. 1997). Less than 1 % of the time does 
significant liver disease like portal hypertension, variceal bleeding, hepatopulmonary 
syndrome and liver failure occur and in terms of lung transplant work up a CT scan of the 
abdomen in combination with laboratory parameters is usually sufficient to assess the 
integrity of the liver and spleen unless indicators such as haematemesis or refractory 
hypoxia are present.  
Cardiovascular investigation represents an important area in patients with Sarcoidosis. 
Clinically cardiac involvement is thought to be 5 percent however cadaveric studies have 
shown the figure to be around 25 percent in one series (Iannuzzi, Rybicki et al. 2007). There 
is a low yield with cardiac biopsies and this hinders the identification of cardiac 
involvement. The likely reason for this is that the left free wall and septum are more 
commonly involved resulting in cardiomyopathy or arrhythmias. While these may be 
identified on routine echocardiography and electrocardiograms the use of MRI/PET with 
gadolinium are useful in screening for cardiac involvement (Ohira, Tsujino et al. 2008).  
Immunosuppression and steroid induced diabetes post lung transplantation results in a 
higher risk of renal impairment. Macrophages in Sarcoidosis granulomas activate 25-
hydroxy-vitamin D to 1,25-dihydroxyvitamin-D resulting in hypercalcaemia (11%), 
hypercalciuria (40%) and renal calculi (10%) while intrarenal calcium deposition can result 
in renal failure (Berliner, Haas et al. 2006). All represent a potential risk to patients post 
transplantation and so patients are screened with 24-hour urinary calcium excretion 
examination, 24-hour creatinine clearance, and CT abdomen is also performed. 
Eighty percent of patients have ocular Sarcoidosis manifest by anterior and posterior uveitis. 
(Atmaca, Atmaca-Sonmez et al. 2009). This needs to be flagged in the pre-transplant clinic, 
as there is the added complication of steroid induced cataracts in the post-operative period. 
In addition there is an increased incidence of neurological Sarcoidosis associated with 
anterior uveitis, while neurosarcoid is only symptomatic 10% of the time any neurological 
symptoms should be investigated with an MRI with gadolinium (Menezo, Lobo et al. 2009). 
A positive result with significant symptoms would rule out transplantation.  
3.3 Types of surgery 
Sarcoidosis has been subject to most modes of lung transplantation over the decades 
however some are more advantageous than others. Heart lung transplantation was initially 
performed and can still be offered if the heart is deemed likely to be unrecoverable post 
transplant. This is not commonly performed now because experience has taught us that the 
heart can recover quite well after transplantation (Bando, Armitage et al. 1994), however, 
even for those in whom the heart is too impaired the paucity of donors has meant the 
numbers have dwindled over time.  
Single lung transplantation on the other hand maximizes the donor pool and increases the 
chance for more patients on the list to be successfully transplanted. There is some debate 
as to whether single lung transplantation leaves the patient more susceptible to earlier 
decline in lung function due to the deficiency of the extra tissue. However we have 
previously published on our data showing a strong long-term survival in patients 
receiving a single lung transplant for interstitial lung disease of all types (Keating, Levvey 
et al. 2009).  
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Table 3. Lung Transplant work-up protocol 
Laboratory Studies    Full blood count & Coagulation testing 
Urea, creatinine and electrolytes  
Calcium, phosphorous, amylase  
Liver & Thyroid function tests  
Total protein and albumin  
Fasting lipids  
24-hour urinary creatinine clearance 
Urine analysis including cotinine 
 
Microbiology and Serology    Sputum analysis - bacterial and fungal cultures 
Tuberculosis – Quantiferon Testing 
Syphilis - RPR, VRDL 
Urine culture 
Cytomegalovirus, Epstein Barr virus, 
toxoplasmosis, Varicella-zoster virus, herpes 
simplex virus,  
Human immunodeficiency virus 
Hepatitis A, B, and C virus  
 
Immunologic Assessment   ABO blood typing 
Lymphocytic cytotoxic antibody crossmatch 
Human leukocyte antigen typing  
Lymphocyte cytotoxicity screen  
Quantitative immunoglobulin and subclasses 
 
Cardiac Assessment                      12-lead electrocardiogram 
Cardiac gated blood pool scan 
Echocardiogram 
Thallium stress testing 
Cardiac catheterization – if > 40 yrs  
coronary arteries & ventriculogram,  
+/- right heart catheter  
+/- Cardiac Magnetic Resonance Imaging  
 
Pulmonary Assessment    Spirometry, DLCO, lung volumes,  
arterial blood gases 
Computed Tomography of the chest 
Ventilation-perfusion scan 
Chest x-ray - PA and lateral, and AP supine 
Exercise capacity - 6-minute walk test with pulse 
oximetry 
 
Vaccines                         Human papilloma vaccine in females  
Pneumococcal Vaccine 
Hepatitis A (if seronegative) 
Hepatitis B (if seronegative) 
 
Miscellaneous    Gynaecological exam & Mammogram > 35 years 
DEXA scan of spine and hips 
Prostate-specific antigen >55 years 
Nutritional assessment including BMI 
Dental evaluation 
Psychosocial Evaluation 
Physiotherapy consultation 
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Others have also suggested that due to the shorter operation time single lung 
transplantation may be preferable for those who might benefit from a brief anesthetic 
exposure (Low, Trulock et al. 1992). 
There are however particular situations where bilateral sequential lung transplantation is 
more advantageous. This particularly applies to Sarcoidosis patients who have stage IV 
disease. In this setting the presence of traction bronchiectasis and the presence of resistant 
microbes make the necessity for this procedure absolute. It is not advisable to leave a 
potentially infected native lung in situ if there is evidence that it harbors resistant organisms 
such as pseudomonas aeruginosa, scediosporum profligans or aspergillus.  So while there is 
no research suggesting one form of surgery is superior to another in survival terms, some 
authors suggest bilateral transplantation should be performed on patients with severe 
secondary hypertension, fibrocystic Sarcoidosis, mycetomas, and bronchiectasis (Alalawi, 
Whelan et al. 2005). 
Sarcoidosis patients most commonly have a restrictive lung disease and as a result lung size 
is diminished. In order to accommodate the change in size the lung function is used to 
compute the size a potential match should be. If there is a size discrepancy it may be 
necessary to perform cadaveric lobar lung transplantation. This may also be the result if 
there is a pediatric recipient, when the decision to perform a lobar cut down can be 
electively taken at the time of listing. Outcomes from this type of surgery are similar to other 
surgeries allowing patients previously discriminated against based on size mismatch to be 
transplanted successfully (Keating, Marasco et al. 2010). For similar reasons living donor 
lobar lung transplantation was developed in order to decrease waiting list times. While 
there is a theoretical 300% mortality risk, to date this has procedure has shown itself to be 
well tolerated (Barr, Schenkel et al. 2005). Its use has diminished recently following the 
introduction of the lung allocation score in the United States however it is still used in 
countries where culture differences with regards to brain death are still hindering donor 
procurement.  
While the type of surgery being performed has changed, so too has the method by which it 
is performed. Bilateral sequential lung transplantation has superseded the en bloc approach. 
The use of lung transplantation over heart-lung transplantation has also developed as our 
experience has grown. The approach has also differed from midline approach to a clamshell 
horizontal incision. This now has also been modified in certain individuals to a bilateral 
thoracotomy incision that allows adequate access to the thoracic cavity but leaves the 
sternum intact. When patients such as those with Sarcoidosis have had significant exposure 
to corticosteroids then sternal healing may be impaired and by using this approach a more 
satisfactory outcome can be achieved. 
3.4 Perioperative considerations 
A number of issues need to be considered on the night of transplant specifically when 
considering the multiorgan involvement associated with Sarcoidosis. It is crucial that while 
on the waiting list that all personnel with a role in the transplant process are kept abreast of 
any new developments that might arise. This is usually achieved by regular outpatient 
review with follow up debriefing session with staff. It is through this attention to detail that 
allows coordinators, physicians and operators to organize a smooth transition through the 
procedure. 
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As part of workup patients are screened for renal impairment, if there is any suggestion that 
renal function may deteriorate as a result of the procedure it is possible during the 
perioperative period to consider alternative strategies. This might include include 
withholding preoperative immunosuppression and alternatively using Basiliximab a 
chimeric monoclonal Interleukin-2 receptor antibody with less nephrotoxicity than 
calcineurin inhibitors Tacrolimus and Cyclosporin. It acts as an antagonist at the interleukin-
2 binding site of the p55 subunit of the high affinity Interleukin-2 receptor on the surface of 
the activated T lymphocytes and has been shown to decrease the incidence of acute rejection 
but not chronic rejection in lung transplant recipients (Borro, De la Torre et al. 2005).  
3.4.1 Anesthetic considerations 
As the fibrotic component of the disease advances Sarcoidosis patients develop tracheal 
deviation (Figure 1A). While in the majority of the cases this is not a significant issue there is 
a minority of patients who present on the night of transplant with a severely distorted 
trachea. This represents a particular problem for anesthetic staff with responsibility for 
inserting a double lumen endotracheal tube to allow independent lung ventilation necessary 
to perform a bilateral sequential lung transplant. In most cases this can be achieved, 
however it adds to the ischaemic time if there is a large time delay. 
Routine preoperative anesthetic care involves the insertion of an epidural to adequately titre 
pain relief post operatively. In patients with severe end stage fibrosis this may be essential 
as they may have been treated preoperatively with opioid agents for excessive dyspnoea 
and distress thereby blunting their response to regular doses of analgesia. While in the usual 
setting this procedure is more routine, in the case of end stage fibrosis patients with labile 
oxygenation and possible vertebral fractures is requires a greater level of competence and 
expertise to ensure success. 
3.4.2 Intraoperative considerations 
Likewise for patients with stage III disease the process may extend to abut or involve the 
pleura. In this scenario it may be surgically challenging to remove the recipient lungs from 
the thoracic cavity. This can be assessed by using computed tomography of the chest and 
assessing the pleural involvement visually, if there is evidence of pleural thickening or 
adhesion it would be prudent to allow more ’dissection time’ when organizing the 
procedure.  
As stated previously the identification of pulmonary hypertension prior to listing is a useful 
indicator for prognosis in patients with Sarcoidosis. In addition this information is also 
crucial on the night of transplantation as there is a higher incidence of patients with 
pulmonary hypertension needing cardiac bypass. This procedure results in deoxygenated 
blood being removed via large bore cannula placed usually in the vena cava, being 
externally oxygenated, filtered, warmed and then returned to the circulation via a second 
large bore cannula usually placed in the ascending aorta. Some debate exists about the need 
for cardiac bypass in routine lung transplantation, however in the setting of pulmonary 
hypertension it can prevent hemodynamic collapse when the pulmonary artery is clamped. 
In addition is prevents any sudden increase in pulmonary pressures after clamping which 
might increase the after-load on the right ventricle. With underlying hypertension this could 
result in right heart failure and decompensation. As a result most centres will have 
cardiopulmonary bypass on standby in transplant cases where there is evidence of increased 
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pulmonary pressures preoperatively (Marczin, Royston et al. 2000). In some patients with 
severe pulmonary hypertension and high oxygen requirements a decision to commence 
cardiopulmonary bypass prior to induction of anesthesia may be made. This allows the 
anesthetist time to correctly position the endotracheal tube without the risk of sudden and 
catastrophic desaturation occurring. When this is performed a different approach is used 
with cannulation of the femoral artery and vein.  
Hyperacute rejection is one of the more devastating complications that occurs following 
lung transplantation surgery. On releasing the cross-clamp the flow of blood into the new 
lung results in an immediate reaction within minutes that can herald a terminal decline. The 
mechanism is thought to be pre-existing antibodies formed against ABO blood groups, 
endothelial cells or human leukocyte antigens (Frost, Jammal et al. 1996). This results in 
parenchymal damage that pathologically resembles diffuse alveolar damage characterized 
by mononuclear and polymorphonuclear accumulation, intravascular thrombosis and 
intramural vascular necrosis. Many centres now use more sensitive antibody testing such as 
Luminex, which allows a better assessment of the match between donor and recipient. This 
has decreased the incidence of hyperacute rejection and while it still represents a significant 
immediate complication there is some possibility that the patient can be stabilized, 
transferred onto extracorporeal membrane oxygenation and urgently relisted. 
3.4.3 Early post-operative considerations 
Most of the gains that have been achieved in lung transplantation over the last two decades 
have been as a result of early post-operative management. The recognition of problems that 
might arise not just as a result of transplantation but also in relation to the recipients 
underlying disease has allowed physicians to pre-empt issues rather than react to them as 
they arise. Some of the problems that affect Sarcoidosis patients are related to the transplant 
process, however some they will have a predilection to.  
Immunosuppression is commenced pre-operatively and continued post operative while 
being closely followed using serum measurements of trough levels. Most centers use a triple 
immunosuppression regimen consisting of a calcineurin inhibitor (Cyclosporin or 
Tacrolimus), Azathioprine or mycophenylate, and corticosteroids. Basiliximab may be used 
in preference to the calcineurin inhibitors initially to preserve renal function. Preoperative 
assessment in Sarcoidosis patients usually highlights those that should be prescribed the 
Interleukin-2 inhibitor electively. All agents can be given intravenously initially and 
changed to the oral route when feasible (Snell and Westall 2007). 
Ischemia reperfusion injury is used to describe non-cardiogenic edema that usually occurs 
approximately 24 hours after lung transplantation in up to 97% of patients. It peaks by day 
four, resolving usually by day seven however, it may continue for up to six months. 
Putative contributing factors include surgical trauma, donor lung ischemia, and interruption 
of bronchial circulation, lymphatic flow and donor lung innervation (Collins 2002). Features 
of reperfusion injury on Computed Tomography differ from those of hyperacute rejection 
with evidence of perihilar ground glass opacities, peribronchial and perivascular thickening 
and reticular interstitial or airspace opacities especially in the middle and lower lobes. In 
this setting it is important to rule out other causes with similar profiles such as rejection, 
infection, fluid overload or cardiac failure especially in Sarcoidosis patients with an 
increased incidence of cardiac involvement (Krishnam, Suh et al. 2007) 
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To avoid healing problems that may occur it is important not to induce barotrauma either to 
the parenchyma, which might induce an upregulation of the immune response, or direct 
positive pressure injury to the anastomotic area. While strategies need not necessarily be 
tailored for Sarcoidosis patients a strategy of low positive end expiratory pressure (5cmH20) 
and tidal volumes (8-10 mL/Kg) are preferred. When patients receive single lung 
transplants this is especially important as the native lung will have altered compliance due 
to fibrosis putting the allograft at greater risk of injury using what appears to be acceptable 
pressures 
Early weaning from mechanical ventilation is of paramount importance for a successful 
transplant outcome. Many patients can be weaned from the ventilator within twenty-four 
hours. This has significant benefits in terms of weaning of sedation, less need for airway 
access via suction, while the risk of infection is considerably reduced. In addition the 
discontinuation of positive pressure and the initiation of more natural negative ventilation 
helps to protect the anastomotic integrity from any barotrauma that might cause rupture. 
An early extubation strategy for Sarcoidosis recipients is encouraged as many patients will 
have been treated with prolonged courses of steroids. While this is not a contraindication for 
transplantation there are a number of problems that might arise if the overall burden of 
steroid preoperatively is excessive. Of particular concern is the patients’ wound healing 
ability following surgery. This does not only apply to the cutaneous and underlying 
subcutaneous structures but also the anastomoses. The arterial and venous connections may 
also be compromised by significant corticosteroid doses. As a general rule most centres 
suggest doses of steroids to be less than 10 milligrams per day prior to transplantation, 
which in the majority of Sarcoidosis cases can be achieved.  
Weaning from mechanical ventilation may also be affected more profoundly by the onset of 
critical care myopathy. While there is no indication that this affects patients with Sarcoidosis 
more than any other transplant recipients the long-term use of steroids in high doses 
certainly results in preponderance for muscle wasting (Weber-Carstens, Deja et al.). The 
wasting of intercostal muscles in particular may result in failure to wean from the 
mechanical ventilator resulting in the need to progress to tracheostomy placement and non-
invasive ventilation strategies to aid recovery. A prolonged period on non-invasive 
ventilation through a tracheotomy leads to thicker secretions, increased frequency of 
infections and increased length of stay. 
The diaphragm represents the main muscle of respiration and normal ventilation requires it 
to be healthy and functioning. Normal diaphragmatic contraction results in decreased 
intrapleural pressure, an expanded rib cage through its zone of apposition by generating a 
positive intra-abdominal pressure, and expansion of the rib cage using the abdomen as a 
fulcrum (Rochester 1985). The reported incidence of phrenic nerve injury in the literature 
varies from 3% to 30% and is dependent on the methods used to detect the defect (Maziak, 
Maurer et al. 1996). The putative causes of the injury include direct phrenic nerve injury 
during mediastinal dissection, stretch injury of the nerve as the pericardium is manipulated, 
and hypothermic injury during the operative period. Interruption of this phrenic nerve 
function leads to increased work of breathing and difficulty in weaning patients from 
mechanical ventilation in addition to an increased incidence of atelectasis, ventilator 
associated pneumonia, and hypoxemia resulting in prolongation of ICU stay in most cases 
(Maziak, Maurer et al. 1996; Ferdinande, Bruyninckx et al. 2004) 
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 Physiotherapy input at this stage and indeed in the preoperative work up is essential to 
improve patient outcome (Kress 2009). Breathing techniques to facilitate airway secretion 
clearance and daily assessment of muscle function help to expedite patients’ recovery and 
decrease infections. An earlier initiation of treatment and regular follow up exercise, in a 
controlled environment, has long term benefits on patients exercise capacity, lung function 
and quality of life (Munro, Holland et al. 2009).  
3.4.4 General ICU considerations 
Usually an epidural catheter placed preoperatively allows adequate analgesia to be applied 
at a local level and decreasing the reliance on systemic agents. If this is not possible higher 
doses of systemic agents may result in significant cognitive depression delaying weaning 
from mechanical ventilation. In addition any prolongation of mechanical ventilation should 
be accompanied by an attempt to awaken the patient on a daily basis to assess cognitive 
function, pain threshold and ability to perform even limited physiotherapy.   
Although more commonly seen as a result of gastric surgery there has been a recent increase 
in the reported incidence of vagus nerve injury following fundoplication surgery and 
bariatric surgery. However, there have been reports of cases in transplantation also (Shafi 
and Pasricha 2007; Paul, Escareno et al. 2009)with the incidence reported to be of the order 
of five percent. Most cases can be managed conservatively; however there may be 
significant problems post lung transplantation in terms of maintaining adequate 
immunosuppression and nutritional absorption. Most injuries resolve over a two-year 
period and additional intervention is not usually required.  
Malabsorption however can have additional consequences with patients often having 
difficulty maintaining electrolyte levels. While patients with cystic fibrosis are generally at 
greater risk any Sarcoidosis patients who may have occult cardiac involvement may 
manifest this during a period of electrolyte instability by the onset of cardiac arrhythmia. 
Patients are monitored daily with blood analysis while immunosuppression levels are 
increased to achieve adequate levels. Any evidence of renal impairment or electrolyte 
imbalance is treated early to avoid any cardiac arrhythmias. 
Hyperammonemia has been reported to occur in up to four percent of lung transplant 
patients with mortality estimated to be of the order of seventy percent (Lichtenstein, Yang et 
al. 2000). It presents as a clinical syndrome with deteriorating neurological function despite 
liver function tests in the normal range within the first three months after surgery. 
Hyperammonemia is thought to be related to immunosuppressive agents however 
underlying liver and genetic abnormalities have also been suggested as alleged mechanisms 
of disease. Sarcoidosis patients although not shown to be at higher risk post lung transplant, 
may have occult disease wither due to granulomatous infiltration or to immunosuppressive 
agents such as azathioprine prescribed preoperatively. While the prognosis if diagnosed is 
poor there have been reports of patients being successfully managed, physicians however, 
need to maintain a high level of clinical suspicion to facilitate early intervention (Moffatt-
Bruce, Pesavento et al. 2008) 
3.4.5 Infections 
Early infections are usually of donor origin however in the setting of severe bronchiectasis 
as in stage IV Sarcoidosis it is possible to have native tracheal colonization with microbes. 
Early antibiotic regimens are usually broad spectrum covering the commonest pathogens 
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with the addition of cover for any microbes identified in the recipient preoperatively. Donor 
harvest washings are also taken to tailor the treatment if empiric treatment proves to be 
incomplete.  
Bacterial pneumonia is frequently observed following lung transplantation; however the 
incidence has decreased over the last few decades. The initial six-month post operative 
period is when the patients are subjected to the peak level of immunosuppression and it is 
during this time that likelihood of bacterial infection is at its greatest. Bacterial identification 
has been reported in up to eighty percent of patients. In one Spanish study there was an 
incidence of 72 episodes of pneumonia per hundred lung transplants per year and of the 
established etiologies bacterial infections accounted for eighty two percent. Pseudomonas, 
Acinetobacter and staphylococcus accounted for the majority of the cases (Aguilar-Guisado, 
Givalda et al. 2007). Assessment and sampling of donor lungs during harvesting suggests 
that many of the early pneumonias are of donor origin; use of this information has allowed a 
tailoring of the post lung transplant antibiotic regime resulting in improved outcome 
(Dauber, Paradis et al. 1990; Weill, Dey et al. 2002). Antibiotic prophylaxis against 
opportunistic infections is also important and the use of sulfamethoxazole and trimethoprim 
three times a week has been efficacious in the prevention of Pneumocystis Jiroveci infection 
while it also has an effect on other microbes such as Listeria, Toxoplasma and Listeria 
(Fishman 2007). 
Cytomegalovirus (a human herpesvirus) is probably the most important viral pathogens 
associated with lung transplantation due to its ability to latently infect the host allowing 
reactivation to occur at any stage throughout the recipients lifetime (Zamora 2004). 
Seronegative recipients receiving a seropositive allograft are at greatest risk of infection 
while previously exposed recipients have a lesser risk. CMV primary infection and 
reactivation is associated with a reported mortality ranging from 2- 12 percent (Fishman and 
Rubin 1998). While the acute effects from CMV have been identified the long term risk from 
latent infection or repeated activation does not have a linear relationship with the 
development of chronic allograft failure (Sharples, McNeil et al. 2002).  
Epstein Barr Virus is a well-documented pathogen following lung transplantation with 
historical reports of post transplant lymphoproliferative disease in 2-5% of all lung 
transplant recipients and up to 30% of donor/recipient Epstein Barr virus mismatches. More 
recently, routine use of current antiviral prophylaxis strategies, more judicious use of 
immunosuppression regimens in at risk recipients, and improved treatment options have 
anecdotally been associated with improved outcomes (Malouf, Chhajed et al. 2002). 
Other viruses such as the alphaherpesviridae (Herpes Simplex Virus 1 and 2, and Varicella 
Zoster Virus) were previously associated with an unacceptably high mortality however with 
cytomegalovirus prophylaxis the 10 percent mortality associated with these viruses has been 
almost eradicated (Manuel, Kumar et al. 2008)  
While fungal infections post lung transplantation may include Candida, Scediosporum and 
Fusarium species the most problematic is Aspergillus. Aspergillus, also the commonest 
affecting 6.2% of all lung transplant recipients (Singh and Husain 2003), may take the form 
of tracheobronchitis, anastomotic infection of parenchymal invasion, although disseminated 
disease can also occur. Complicated surgery in addition to immunosuppressive therapy and 
renal impairment are recognized as risk factors for fungal infection, suggesting that extra 
vigilance may be warranted in Sarcoidosis patients in the weeks post procedure. Diagnosis 
of fungal infection is difficult but the instigation of regular surveillance bronchoscopies in 
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most centres allows regular viewing of the anastomosis and bronchoalveolar lavage of the 
parenchyma, which improves the detection rate. Treatment in most centres involves 
fluconazole or in the case of aspergillus voriconazole or posaconazole which has been 
reasonably efficacious in managing the disease although eradication has proven difficult 
especially in the setting of single lung transplant recipients where the native lung acts as a 
reservoir for infection. Prophylaxis is not routinely prescribed unless isolated from the 
donor harvest bronchoalveolar lavage. 
3.4.6 Medium and late complications 
A number of conditions are associated with lung transplantation as a consequence of the long-
term effects of immunosuppression. These include osteoporosis (Aris, Neuringer et al. 1996) 
which many Sarcoidosis patients will have a predilection to as a result of prior corticosteroid 
use, chronic renal failure related in part to Tacrolimus or cyclosporine (Parekh, Trulock et al. 
2004) as is systemic hypertension (Morrison, Short et al. 1993). Corticosteroids and the 
calcineurin inhibitors can also induce diabetes mellitus (Jindal 1994),  Obesity, Anaemia (End, 
Stift et al. 1995), hypercholesterolemia and hypertriglyceridaemia (Stephany, Alao et al. 2007).  
Gastroesophageal reflux disease (GORD) disease however appears to be a direct result of 
surgery through mechanical manipulation or impingement of the vagus nerve causing 
gastroparesis (Davis, Lau et al. 2003). 
Lung transplantation surgery has evolved so that the recipient airway is relying on collateral 
and retrograde perfusion from the pulmonary artery for blood supply. Initially the 
bronchial arteries were re-anastomosed but this resulted in prolongation of the allograft 
ischaemic time; this led to the cessation of this technique. Currently evidence of diminished 
airway perfusion may be observed during surveillance bronchoscopies usually as 
variegated violet change on the endobronchial surface. These changes may subsequently 
develop into ischaemic injury with blackening and ulceration of the surface. Some of the 
sloughed endobronchial surface may result in airway obstruction with evidence of 
decreased FEV1 and a scalloped flow loop on lung function testing. Any sloughed areas can 
be debrided via the bronchoscope and closely followed to insure that secondary infection is 
identified and treated as early as possible. 
For the majority of cases conservative management is sufficient however in 5% of patients 
the injury progresses to bronchial dehiscence with ulceration, perforation or stricture 
formation (Weder, Inci et al. 2009). It has been suggested that the technique of telescoping of 
the airways to adjust for size discrepancy and to add stability to the airway wall may also 
result in an increase in airway complications. Usually management is successful using 
balloon dilatations with or without the added radial cuts with argon plasma coagulation. 
This approach usually abrogates the need to use endobronchial stent placement. In some 
patients the need for stenting is unavoidable and in this scenario temporary polyflex stents 
can be placed which allow for their removal when the integrity of the airway wall has 
stiffened with scaring. Occasionally covered or uncovered stents may be placed and usually 
this will add architecture to the airway, however the disadvantage is that stents can fracture 
leading to retention of secretions around the loose wires. This may result in infection, 
obstruction or both and dealing with these can be problematic as the stents become 
embedded in the walls. On the other hand vascular anastomotic problems are not as 
common. Usually if present they result in pulmonary infarction on the arterial side and 
often occur in the early postoperative period. 
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Surveillance bronchoscopy is carried out regularly after transplantation at weeks 
2,4,8,12,24,36, and 52. While initially this is done to assess the anastomosis and also to 
preempt any infection that might arise subsequently more subtle infections such as CMV 
and EBV can be identified earlier by using bronchoalveolar lavage thereby allowing 
physicians to augment therapy and avoid chronic impairment (Westall, Michaelides et al. 
2004).  
Bronchoscopy is also performed to monitor for acute rejection which in the early post 
operative period is generally diagnosed using clinical criteria. Clinically acute rejection is 
recognized as a constellation of symptoms including dyspnoea, fatigue, dry cough, low-
grade fever, a 10mmHg decrease in PaO2, and a 10% drop in FEV1 in conjunction with 
radiological opacification. These clinical features are not specific and usually develop when 
acute rejection is more severe. Subsequently surveillance biopsies taken at bronchoscopy 
assist to diagnose the process. Acute rejection occurs when the host organ recipient 
recognizes the donor organ as foreign, based on a lack of recognition of human leukocyte 
antigens, and as a result attacks the organ causing it to fail. Acute rejection is classified 
based on the severity and extent of perivascular lymphocytic cuffing and parenchymal 
infiltration. No abnormality (grade A0) at one end of the scale is counterbalanced by severe 
rejection (grade A4) that involves the interstitium and airspaces in addition to damaged 
pneumocytes and vascular changes (Stewart, Fishbein et al. 2007).  Most lung transplant 
recipients will develop at least one episode of acute rejection in the first three months and 
the presence of rejection grade A2 or higher is managed with a ‘pulse’ of 
methylprednisolone (500mg-1g IV x three days). Baseline immunosuppression is also 
augmented following this. Resistant cases may need further treatment with antilymphocyte 
antibody. 
Chronic rejection remains the elusive ‘holy grail’ of transplantation. It remains the main 
cause of morbidity and mortality after the first year not just due to obliterative bronchiolitis 
but also due to increased infections (Burton, Carlsen et al. 2007). Chronic rejection is more 
difficult to diagnose and has a more languid onset than acute rejection. Patients usually 
develop a cough that may be productive and clinically produce audible squeaks on 
examination. Risk factors to be noted in the history include persistent or severe episodes of 
acute rejection, CMV infection or recurrence, organising pneumonia, ischaemic-reperfusion 
injury, and gastro-oesophageal reflux (Estenne, Maurer et al. 2002). Lung function may 
show a progressive obstruction which has been used to grade the severity of bronchiolitis 
obliterans syndrome while the pathological entity obliterative bronchiolitis may or may not 
be evident on transbronchial biopsies leaving clinicians with a diagnosis of exclusion. 
Treatment is generally unsatisfactory despite courses of pulsed corticosteroids, cytolytic 
therapy, inhaled cyclosporin, switching from Cyclosporin to Tacrolimus, total lymphoid 
irradiation, plasmapheresis and photopheresis, leaving retransplantation in most cases the 
only option provided the patient passes the assessment criteria a second time (Neuringer, 
Noone et al. 2009). 
4. Results 
Considering the numbers of transplants performed for Sarcoidosis are limited compared 
with other diagnosis, the specific survival data is difficult to extrapolate from the 
documented figures provided in international databases. Lung transplantation figures have 
generally improved recently, due mainly to careful choice of donors and improvements in 
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patient management postoperatively. Recent data shows that for all deceased donor lung 
transplants the 1, 3, and 5 year survival is 83, 65 and 51 percent respectively (UNOS 2011). In 
order to address the donor shortage donor organs from patients deceased following cardiac 
death have been utilised, and interestingly the early outcome data suggests that the survival 
is improved in this cohort theoretically due to diminished neurological mediators released 
at the time of death although the exact reason remains to be elucidated (Snell and Levvey 
2009). No direct comparison of data has been published; however one paper has shown 
excellent long term outcomes for all interstitial diseases following transplantation, which 
appears comparable to survival numbers in other organs (Keating, Levvey et al. 2009). 
 
 Living Deceased 
Lost to 
Follow up 
Retransplanted Total 
Year N % N % N % N % N 
2000 10 38.46 16 61.54 0 0 0 0 26 
2001 7 22.58 22 70.97 0 0 2 6.45 31 
2002 5 15.63 24 75.00 1 3.13 2 6.25 32 
2003 9 42.86 11 52.38 1 4.76 0 0 21 
2004 16 41.03 21 53.85 1 2.56 1 2.56 39 
2005 19 39.58 27 56.25 1 2.08 1 2.08 48 
2006 36 64.29 18 32.14 1 1.79 1 1.79 56 
2007 25 58.14 17 39.53 1 2.33 0 0 43 
2008 32 74.42 11 25.58 0 0 0 0 43 
2009 37 82.22 7 15.56 0 0 1 2.22 45 
2010 45 83.33 9 16.67 0 0 0 0 54 
All 241 55.05 183 41.78 6 1.37 8 1.83 438 
Table 4. Survival Data from UNOS for Sarcoidosis Recipients since 2000 
Other research shows that Sarcoidosis patients, when compared to other lung transplant 
recipients, have a predilection for severe, acute rejection. Acute rejection is a recognised risk 
factor for the development of BOS or chronic rejection suggesting Sarcoidosis patients might 
have a worse long term outcome after transplant (Johnson, Duncan et al. 1993). On review 
the evidence for an increased incidence of BOS in Sarcoidosis patients is lacking and 
suggests that the numbers involved in this study are too small to draw definitive 
conclusions on long term outcomes while others have shown equivocal outcomes to other 
transplant diagnosis (Padilla, Schilero et al. 1997; Wille, Gaggar et al. 2008; Keating, Levvey 
et al. 2009). 
A number of cases of Sarcoidosis have recurred post lung transplantation (Bjortuft, Foerster et 
al. 1994; Gisvold, Crotty et al. 2000), however only 533 patients with Sarcoidosis are registered 
as receiving a transplant since 1998 (OPTN/SRTR 2009 ). Because of the small number of 
recipients with a primary diagnosis of Sarcoidosis the actual prevalence of recurrence is not 
known definitively. To date around 21 cases are recorded with two further reports of 
recurrence in an undocumented number (Collins, Hartman et al. 2001). The estimated 
frequency is calculated as 50% but the range between reported series has been between 25 and 
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80% (Johnson, Duncan et al. 1993; Bjortuft, Foerster et al. 1994; Walker, Mikhail et al. 1998; 
Burke, Stewart et al. 2001; Milman, Burton et al. 2005). Although rates are varied Black 
Americans seem to have a higher recurrence rate at 66% compared to other races (Nunley, 
Hattler et al. 1999). Sarcoidosis, however, is not the only disease that recurs following lung 
transplant and a list of the other reported conditions is in Table 2. 
In the majority of cases, recurrence of Sarcoidosis is not preceded by an increase in 
respiratory symptoms and signs (Johnson, Duncan et al. 1993; Nunley, Hattler et al. 1999). 
Usually cases of recurrence are identified as part of surveillance bronchoscopies carried out 
routinely post procedure. Recurrence is evidenced by the identification of the characteristic 
non-caseating granulomas present before transplantation however other causes of this such 
as fungal or mycobacterial infection need to be ruled out first. Radiologically the features 
may be of solitary or multiple nodules, or there may be no specific changes present (Collins, 
Hartman et al. 2001). In some cases however there may be evidence of graft dysfunction 
with the onset of respiratory symptoms, and in these patients there is a greater likelihood 
that there are coexisting infiltrates on radiological investigations (Judson 1998).  
 
 
Table 5. Table of conditions known to recur after lung transplantation. 
Recurrence can occur at any stage post transplantation documented from as early as 2 weeks 
out to 2 years (Johnson, Duncan et al. 1993; Martel, Carre et al. 1996). Some have suggested 
that rejection and Sarcoidosis may utilise a common pathway via the activation of T-
lymphocytes however, the weight of evidence is against this. Immunosuppression used in 
lung transplantation to target interleukin-2, part of the CD8 cytotoxic T-lymphocyte 
response, has been found to be ineffective in suppressing Sarcoidosis, the granulomas of 
which appear to be due to a process driven by CD4 T-lymphocytes (Semenzato, Zambello et 
al. 1993; Wyser, van Schalkwyk et al. 1997). The recurrence of Sarcoidosis in lung transplant 
recipients early post operatively when immunosuppression is at its zenith would concur 
with a disparate immunological basis between the two pathological processes.  
Notwithstanding the debate as to the frequency of recurrence of Sarcoidosis the impact of 
recurrence appears to be negligible. The majority of patients who have recurrence have an 
incidental finding with little or no effect noticeable on pulmonary function testing. Indeed 
while recurrence is associated with a more severe course of acute rejection, there is no 
evidence for increased frequency and there is no association with an increase in BOS over 
and above the normal LTx population.  
Sarcoidosis 
Lymphangioleiomatosis 
Diffuse Panbronchiolitis 
Pulmonary alveolar proteinosis 
Desquamative interstitial pneumonia 
Pulmonary Langherhans Cell Histiocytosis 
Bronchioloalveolar Carcinoma 
Idiopathic Pulmonary Hemosiderosis 
Giant Cell Interstitial Pneumonia 
Alpha-1-Antitrypsin Deficiency 
Pulmonary Veno-occlusive Disease 
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Appropriate patients are considered for retransplantation if they are in robust enough 
health to allow transition through a second procedure. The evidence suggests that while the 
survival figures are improving retransplantation outcomes are not as good as those 
undergoing their first procedure. This is especially so for those who require early 
retransplantation within 30 days (Trulock, Edwards et al. 2003). A recent paper suggested 
Sarcoidosis was not a significant cause for retransplantation; of 389 patients requiring 
retransplantation between 1980 and 2006, only 84 patients had diffuse lung disease as the 
reason for initial transplantation, this number included all Sarcoidosis patients. The reason 
for retransplantation included BOS (52%), primary graft dysfunction (16%) and acute 
rejection (3%) while all other and unknown causes accounted for only 27% (59/389) (Kawut, 
Lederer et al. 2008). The specific Sarcoidosis numbers among these figures were not 
commented on, however, a previous study showed that there was no evidence to suggest a 
higher incidence of chronic rejection with Sarcoidosis (Padilla, Schilero et al. 1997). This 
taken in conjunction with the UNOS data in Table 4 shows that very few Sarcoidosis 
patients progress to retransplantation (n=8, 1.83%).  
5. Conclusion 
Sarcoidosis continues to affect significant numbers of the population and while many among 
this cohort spontaneously recover some progress to respiratory failure. The historical difficulty 
in Sarcoidosis patient receiving lung transplantation is likely to be multifactorial as the natural 
progression of the disease is not consistent, with no reliable markers to predict those who 
progress despite treatment. This meant that timing for lung transplantation was difficult to 
assess accurately. Recently pulmonary hypertension has been identified as a reasonable 
prognostic marker and all patients who develop increased pulmonary pressures on 
echocardiogram should be considered potential candidates. The multisystem nature of 
Sarcoidosis means patients still need to undergo a rigorous pre-listing assessment, but once 
lung transplantation has been performed outcomes are equivocal to other indications. 
Recurrence of Sarcoidosis is the commonest for all the indication for transplantation however 
it has limited impact on the long-term outcome of the recipient. The development of an LAS in 
score in the United States may result in Sarcoidosis receiving greater priority in the future, 
especially those patients with associated pulmonary hypertension. Early recognition of 
declining clinical and radiological status should prompt referral for lung transplant 
assessment with outcomes likely to improve with further improvements in transplantation. 
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